SCHEMBL880728

SCHEMBL880728

N=C(N)NCCCCC(N)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.52
OTC P00480 1/20 0.50
NOS2 P35228 7/20 0.49
NOS1 P29475 5/20 0.49
NOS3 P29474 4/20 0.49
DDAH1 O94760 3/20 0.47
ARG2 P78540 4/20 0.47
ARG1 P05089 3/20 0.47
CYP1A2 P05177 2/20 0.46
TSHR P16473 2/20 0.46
CYP3A4 P08684 1/20 0.46
GLA P06280 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
CYP2C19 P33261 1/20 0.46
BLM P54132 2/20 0.45
ALOX15 P16050 1/20 0.44
PMP22 Q01453 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43287 1.00 GSR (0.52) GSROTCNOS2NOS1NOS3
SCHEMBL28754154 1.00 GSR (0.52) GSROTCNOS2NOS1NOS3
SCHEMBL10071054 1.00 GSR (0.52) GSROTCNOS2NOS1NOS3
SCHEMBL27615800 1.00 GSR (0.52) GSROTCNOS2NOS1NOS3
Arginine SCHEMBL5152371 0.98 OTC (0.53) GSROTCNOS2NOS1NOS3
SCHEMBL4221548 0.98 GSR (0.50) GSROTCNOS2NOS1NOS3
SCHEMBL4225929 0.98 GSR (0.50) GSROTCNOS2NOS1NOS3
SCHEMBL4225043 0.98 GSR (0.50) GSROTCNOS2NOS1NOS3
Hydrochloric Acid SCHEMBL21045047 0.98 GSR (0.50) GSROTCNOS2NOS1NOS3
SCHEMBL4405593 0.98 GSR (0.50) GSROTCNOS2NOS1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101602-A1 ANTIMICROBIAL PEPTIDES AND METHOD OF PREVENTING OR TREATING INFECTION BY USING THE SAME NATIONAL TAIWAN UNIVERSITY (TW) 2024-03-28 US claimed
EP-4251277-A1 ANTIMICROBIAL PEPTIDES AND METHOD OF PREVENTING OR TREATING INFECTION BY USING THE SAME Academia Sinica (TW) 2023-10-04 EP claimed
WO-2022115510-A1 ANTIMICROBIAL PEPTIDES AND METHOD OF PREVENTING OR TREATING INFECTION BY USING THE SAME ACADEMIA SINICA (TW) 2022-06-02 WO claimed
CN-111621267-B Environment-friendly hyperbranched poly-guano acid shale intercalation inhibitor 西南石油大学 2022-04-01 CN claimed
US-11124818-B2 Method for modifying microcystins and nodularins CYANO BIOTECH GMBH (DE) 2021-09-21 US claimed
US-20200377922-A1 METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS CYANO BIOTECH GMBH (DE) 2020-12-03 US claimed
CN-111621267-A Environment-friendly hyperbranched poly-guano acid shale intercalation inhibitor 西南石油大学 2020-09-04 CN claimed
US-20040074504-A1 Method and composition for inhibiting cardiovascular cell proliferation COOKE JOHN P (US) 2004-04-22 US claimed
US-6605115-B1 Method and composition for inhibiting cardiovascular cell proliferation BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2003-08-12 US claimed
US-20030055053-A1 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives PFIZER INC. 2003-03-20 US claimed
JP-2003501393-A 2003-01-14 JP claimed
EP-1189623-A2 METHOD AND COMPOSITION FOR INHIBITING CARDIOVASCULAR CELL PROLIFERATION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2002-03-27 EP claimed
US-20020016297-A1 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives LINDE ROBERT G (US) 2002-02-07 US claimed
EP-1113008-A1 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents Pfizer Products Inc. (US) 2001-07-04 EP claimed
WO-2000074701-A2 METHOD AND COMPOSITION FOR INHIBITING CARDIOVASCULAR CELL PROLIFERATION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2000-12-14 WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 EP disclosed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 EP disclosed
US-4659691-A ANTIFERTILITY AGENTS MERCK & CO., INC. (US) 1987-04-21 US disclosed
EP-0190946-A2 Novel cyclic hexapeptide LHRH antagonists MERCK & CO. INC. (US) 1986-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055053-A1 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives UMPS, UPP1, UGP2 GSR 2888/4885OTC 564/4885NOS2 3729/4885
US-11124818-B2 Method for modifying microcystins and nodularins NRDC, NGLY1, NLN GSR 2455/4885OTC 95/4885NOS2 265/4885
US-20020016297-A1 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives UMPS, UPP1, NUDT1 GSR 2726/4885OTC 511/4885NOS2 3560/4885
US-20200377922-A1 METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS NRDC, NGLY1, NLN GSR 2627/4885OTC 87/4885NOS2 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.